Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David A. Hyman, MD, JD, on Inclusive Shared Savings

Welcome and Introduction to Vi3C

Jan

Today In Oncology

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Related Videos

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David A. Hyman, MD, JD, on Inclusive Shared Savings

Welcome and Introduction to Vi3C

Genomic Classifier Tests May Influence Treatment Decisions in Prostate Cancer Despite Lack of Evidence for Long Term Outcomes

Effect of KRAS Mutation Status on Treatment Outcomes in Metastatic Pancreatic Adenocarcinoma

Talquetamab Plus Teclistamab in Relapsed or Refractory Multiple Myeloma

Telephone Based Therapy May Reduce Fatigue Interference With Functioning in Metastatic Breast Cancer Survivors

Imlunestrant Alone or With Abemaciclib An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer